Ready-to-use, CE-IVD antibodies for pathology
|
|
|
- Louise Harmon
- 6 years ago
- Views:
Transcription
1 A-1-Antichymotrypsin A-1-Antitrypsin Abcc3 Aberrant Endothelial 4A11 Cell ACTH BSB-25; AH26 Actin 1A4 Actin, Muscle Specific HHF35 Actin, Smooth Muscle BSB-15 (ASM/H12) Adenovirus 20/11 and 2/6; A A Adipophilin / ADRP BSB 91 Afp C3 AldH1A1 EP168 ALK SP144; EP302 Alk/P80 SP8 ALK-1 RBT-ALK1 Alpha Actinin JLN20 Alpha Synuclein BSB-114 Alpha-1-1A88 Antichymotrypsin Alpha-1-Antitrypsin Alpha-Fetoprotein BSB-23; EP209 AMACR / P504S 13H4; RBT-AMACR Amyloid A EP335 Amyloid Beta RBT-A4 Androgen Receptor BSB-4 (AR-D12); F Annexin A1 BSB-95 Apolipoprotein E EP1373Y Arginase-1 EP261 ATRX BSB-108 B7H3/CD276 RBT B7H3 BAP1 BSB-109 Bax E63; BCA-225 Cu-18 B-Cell MB2 Bcl-10 BSB-22 Bcl-2 BSB-5 (BCL2/A4); bcl-2/100 Bcl-2 E17; EP36 Bcl-2 Alpha SP66 Bcl-6 BSB-26; LN22 Bcl-6 EP278; RBT-bcl6 Bcl-X E18; EP94 Beta Catenin EP35; E247 Beta-Catenin 14 Beta-Hcg M94138 Beta-Tubulin III SDL3D10 Bfgf bfgf88 BG8 LewisY F3 Bla-36 A27-42 BOB.1 EP114; SP92 Brachyury RPab BRAF V600E RM8 Brca1 Breast Ca. Ag. Bca-225 CU18 C3d C4d EP273; Ca-125 OC125; Ov185:1 Ca-125 EP48 Ca-15-3 DF3 Ca SLE; C241:5:1:4 LI-Cadherin EP86 Cadherin-6 EP217 Calcitonin SP17; EP92; Caldesmon BSB-19 (CALD-31) Caldesmon E89; EP19 Caldesmon Hmw h-cd Calponin BSB-20; CALP Calponin-1 EP798Y Calretinin 2E7 Calretinin EP1798; SP13; Carbonic Anhydrase 9 EP161 Catenine Delta 1 (P120) Cathepsin D C15 Caveolin-1 EP353 CD10 56C6 CD10 EP195 CD103 / ITGAE EP206 CD105 4G11 CD105 EP274 CD105 / Endoglin CD117 T595 CD117 EP10; YR145 CD117 / C-Kit EP10 CD117 / C-Kit / Scf CD11B M01 CD11B/Itam EPR1344; EP45 CD11C EP157; EP1347Y CD123, IL-3Ra BSB-59 (CD123-D3) CD13 38C12 CD13 EP117; EPR4058 CD134 / OX-40 BSB-90 CD138 B-A38 CD138 EP201 CD14 7 CD14 EP128; EPR3653 CD141 EP175 CD146 EP54 CD15 MMA; BRA4F1 CD15 EP272 CD152 / CTLA-4 BSB 88 CD16 2H7 CD16 EP364 CD163 10D6 CD163 EP324
2 CD16A EP169; SP175 CD19 BSB-97 CD19 EP169 CD1a EP80 CD1A O10 CD2 AB75 CD20 L26; CD20/C23 CD205 EP176 CD207 / Langerin EP349 CD207 / Langerin 12D6 CD21 B2 CD21 EP64; SP186; EP3093 CD22 FPC1 CD227 VU-4H5 CD23 1B12 CD23 EP75; CD25 4C9 CD25 RBT-CD25 CD274 / PD-L1 RBT-PDL1 CD279 / PD-1 NAT-105 CD279 / PD-1 EP239 CD29 JB1a CD3 RBT-CD3; EP41 CD3 (T-Cell) PS1; UCHT1 CD3 Epsilon RBT-CD3e; EP449E CD30 Ber-H2 CD30 (Ki-1Ag) Ber-H2; HRS-4 CD31 1A10; JC/70A CD31 (Pecam-1) 9G11 CD33 RBT-CD33 CD34 QBEnd/10 CD34 EP88 CD35 RLB25 CD35 EP197; SP191 CD38 SPC32 CD38 EP135; SP149 CD4 4B12 CD4 RBT-CD4; EP204 CD41/ ITGA2B EP178 CD43 MT1; DFT-1 CD43 SP55 CD43 & CD45Ra MT1 & MB1 CD44 BSB-12; DF1485 CD45 2B11 & PD7/26 CD45 (Lca) LCA88; LJ27.9; PD7/26/16 & 2B11 CD45R MB1 CD45RA 4KB5 CD45Ra (B Cell) MB1 CD45Rb MEM55 CD45Rc (T Cell) MT2 CD45RO UCHL-1 CD48 EP48 CD5 RBT-CD5; RED1; EP77; EP2952 CD5 4C7 CD53 EP179 CD56 123C3.D5; NKH-1 CD57 BSB-10 (CD57/B8); NK-1 CD6 BSB-54 CD61 2f2 CD61 EP2417Y CD63 NKI/C3 CD63 EP211 CD68 KP-1; BY114; BSB-8 (CD68/G2); CD68/G2; KP1 CD7 LP15 CD7 SP94 CD71 10F11; H68.4; T9 CD74 LN2 CD75 LN-1 CD79A JCB117; 11E 3 CD79A EP82; SP18 CD7d EP132 CD7d LP15 CD8 C8/144B; 1A5; T8 CD8 EP334; SP16 CD8 (C-Term) EP1150Y CD82 EP160 CD9 EPR2949 CD90 EP56 CD95 EP208 CD99 BSB-9 (CD99/B5); HO CD99 EP8; EPR3097Y CDK2 RBT-CDK2 CDK4 EP180 Cdw75 (B Cell) LN1 CDX2 EP25 CDX2 CDX2-88 CEA BSB-13 (CEA31); B M-P; CEA88 CEA C-Erbb-2 SP101; SP3 C-Erbb-2 (Her-2/Neu) CB11 C-Erbb-3 (Her-3) RTJ1/A2 Chromogranin A LK2H10; PHE-5 Claudin-1 Claudin-5 EP224 Clusterin / EP181 Apolipoprotein J c-met / HGFR EP1454Y CMV BM204 c-myc 9 E10 c-myc EP121 Collagen III HWD1.1 Collagen IV CIV22; COL-94
3 COX-2 EP293; SP21; RBT- COX2 Cyclin B1 RBT-B1 Cyclin D1 EP12; RBT14; EPR2241(IHC)-32; Cyclin E1 EP126 Cyclin E2 EP454Y Cytokeratin 34βE12/C51/AE1; CK88 Cytokeratin 10 DEK-10 Cytokeratin 10 EP97 Cytokeratin 13 AE8 Cytokeratin 13 EP69 Cytokeratin 14 LL002 Cytokeratin 14 EP61; EP1612Y Cytokeratin 15 EP14; EPR1614Y Cytokeratin 16 EP27; EP1615Y Cytokeratin 17 BSB-33 Cytokeratin 17 EP98 Cytokeratin 18 DC-10 Cytokeratin 18 EP30 Cytokeratin 19 BSB-34; RCK108 Cytokeratin 19 EP72 Cytokeratin 20 Ks20.8; IT-Ks20.8 Cytokeratin 20 EP23; EPR1622Y; EP23 Cytokeratin 35BH11 35betaH11 Cytokeratin 4 6B10 Cytokeratin 4 EP4 Cytokeratin 5 EP24; EPR1600Y; EP42 Cytokeratin 5 & 14 EP24/ EP61 Cytokeratin 5 & 6 D5/16B4 Cytokeratin 5 & 6 EP24/ EP67; EPR1600Y, EPR1602Y Cytokeratin 5 & 6 & EP24/ EP67/EP111 ERG Cytokeratin 5 & ERG EP24/ EP111 Cytokeratin 6 EP67; EPR1602Y Cytokeratin 7 OV-TL 12/30 Cytokeratin 7 EP16; EPR1619Y Cytokeratin 7 & 8 OV-TL12/30 & C51 Cytokeratin 7 & CDX2 EP16/ EP25 Cytokeratin 8 C51 Cytokeratin 8 EP17 Cytokeratin 8&18 B22.1&B23.1; 5D3 Cytokeratin 8&18 EP17 & EP30 Cytokeratin Cocktail AE1/AE3 Cytokeratin HMW AE3; 34βE12 Cytokeratin LMW CAM5.2; AE1 Cytokeratin Pan C11; Lu-5 Cytokeratin, OSCAR OSCAR Cytokeratin17 E27 Desmin D33; 33 Desmin EP15 Desmoglein-3 BSB-61 Desmoglein-3 EP306 DOG-1 1,1 DOG-1 EP332; RBT-DOG1 Dystrophin 1 Dys1 (Dy4/6D3) Dystrophin 2 Dys2 (Dy8/6C5) E Cadherin EP6 E2F4 EP252 Ebv E-Cadherin 36 E-Cadherin EP6 EGFR 31G7 EGFR EP22; EGFR Phospho EP11 EMA E29; Mc5 EpCam E144; EP155 EpCam Ber-EP4; MOC-31 EBV, LMP-1 CS1-4 Er (Insite) ER88 Er Alpha EPR702 (2) Er-Beta ERCC1 EP219 ERG EPR3864; EP111 Estradiol Estrogen Receptor BSB-1 Estrogen Receptor EP1; RBT11 Estrogen Receptor- EP1 Alpha Factor VIII-Related Ag BGX016A Factor VIII-Related Ag Factor XIIIa E980.1 Factor XIIIa EP292; EP3372 Fascin BSB-36; FCN01 Fibronectin F14 Fli1 Fli-1 G Follicular Dendritic CNA.42 Cell FOXA1 / HNF-3A EP277; FOXO1 EP290 FOXP1 EP137 FOXP3 EP340; FSH BSB-55 FSH Galectin-3 9C4 Gastrin GATA3 L GATA3 EP368 GCDFP-15 23A3 GCDFP-15 EP95 GFAP EP13; GFAP GA-5 GH EP267; GH BSB-99
4 Glepp-1 5C11 Glucagon EP74; Glucagon BSB-111 GLUT1 SPM498 GLUT1 EP141 Glutamine Synthetase GS-6 Glycophorin A GA-R2 (HIR2) Glycophorin A+B HIR2 Glypican-3 1G12; GPC3-88 Granzyme B EP230; Gst Pi H S A HSA/E8 H.Pylori BSB-37 H.Pylori EP279; hcg BSB-38 HE4 EP370 Hemoglobin A EP124; Hep. B Core Ag. Hep-Par1 OCH1E5 HER-2 neu BSB-3 (HER-24) HER-2 neu EP3; RBT-HER2 HER2 neu Phospho EP123 HER-3/c-erbB-3 RBT-HER3 HSV I HSV I 10A3 HSV I & II HSV II hgal / GCET2 EP316 Hgh 54/9 2A2 Hgh HHV-8 13B10 HIF-1alpha EP118 Histone H3 Phospho EP233; HLA-DR LN3 hpl EP241; HPV BSB-66 (SB 24) HPV16 CAMVIR-1 Hsp 70 BRM-22 HSP-27 G3.1 IgA BSB-39 IgA IgD EP173; IgG BSB-40; IgG88 IgG IgG4 BSB-96 IgG4 EP138 IgM BSB-41; IgM88 IgM IMP-3 / 1GF2BP3 EP286 Inhibin Alpha R1 Inhibin Alpha EP378 INI-1 25 inos RBT-iNOS Insulin BSB-42; HB125 Insulin EP125 Islet 1 / ISL1 EP283 J Chain JC88 J-Chain SP105 Kappa Light Chain BSB-58; L1C1; K88 Ki-67 BGX-Ki67; Ki88; BGX-297 Ki-67 EP5; EPR3611 Kras Ksp-Cadherin 4H6/F9 LAG-3 / CD223 EP294 Lambda BSB-16 (Lamb14) Lambda Light Chain EP172; SP147; Laminin LEF-1 EP310 LH BSB-53 LH SP132 Lysozyme EP134; Macrophage HAM-56; LN5 Mammaglobin EP249 Mart-1 / Melan A A103; M2-7C10 Maspin BSB 92 Mast Cell Tryptase AA1 MCM2 RBT-MCM2; SP85; EP40 MCM3 EP202 MCM5 RBT-MCM5 MDM2 BSB-64 MDR MDR88 MDR-1 JSB-1 MDR-1 EP271 Melan-A A103 Melanoma PNL2; KBA.62; HMB45 Melanoma Assoc. Ag NKI/C3 Melanoma: HMB-45, HMB-45, A103 & Mart-1 & Tyrosinase BSB-6 Melanoma Gp100 gp100/d5 Melanosome HMB-45 Mesothelia Cell HBME-1 Mesothelin EP140 Mesothelin 5B2 MITF C5/D5; MiTF/A13 MLH1 G ; ES05 MMP-9 EP127; EP1255Y MSH2 G MSH2 RBT-MSH2; SP46; Red2 MSH6 44; 2D4B5 MSH6 EP49 MUC1 BSB-44 MUC1 EP85; EPR1023 MUC2 BSB-45; CCP58 MUC2 EP187 MUC4 8G7; 1G8
5 MUC4 EP256 MUC5 45M1 MUC5AC CLH2 MUC6 CLH5 MUM1 EP190 Mum1/Irf4 SP114 Muscle Actins Actin 88 Cocktail M. tuberculosis Myelin Basic Protein MBP88 Myelin Basic Protein EP207; Myeloid Sp. Ag BM-3; BM-1 Myeloperoxidase EP151; Myf-4 LO26 MyoD1 EP212 Myogenin F5D Myogenin EP162 Myoglobin BSB-104; MG-1 Myoglobin EP87; Myosin MY-32 Myosin Heavy Chain SMMS.1 Myosin, Smooth BSB-17 (SMM-H24) Muscle Napsin A BSB-112; IP64 Napsin A EP205 N-Cadherin EPR1792Y Nestin EP286 NeuN A60 Neuroblastoma NB84a Neurofilament 2F11; NE-14 Neurofilament EP79 Neutrophil Elastase EP223 Ngf Receptor EP1039Y; EP31 Ngf Receptor BSB-18 NKX2.2 EP336 NKX3.1 EP356 NRAS (Q61R) RBT-NRAS NSE BSB-94; MIG-N3 OCT-2 EP115; EPR542 OCT-4 EP143 OLIG2 EP112 Osteonectin OST1 Osteonectin / SPARC BSB 93 p105 Pana 2B3 p120 (Catenin Delta 1) SP63 p120 Catenin EP66; YE372 p16 (Ink4) G p21 DCS-60.2; 4D10 p27 SX53G8; DCS72 p27 (Kip1) Y236 p34 POH-1 p40 ZR8 p53 DO7; 1801; BP53-12 p53 EP9 p57 Kp10 p63 EP174 Pap A40010 Parafibromin BSB-50 Parathyroid Hormone/ BSB-24 PTH Parvalbumin EP300 Parvovirus R92F6 PAX-2 EP235 PAX-5 ZP007 PAX-5 RBT-PAX5 PAX-6 EP341 PAX-8 ZR-1; EP298 Paxillin EP89; Y113 Pcna PC10 Pdcd4 EP102; EPR3432 Pdgf PDGF88 Pdgf PDGFR-B RBT-PDGFRB; Y92 PDX1 EP139 Perforin 5B10 PGP 9.5 BSB-46; 3D9 Placental Lactogen PLAP BSB-47; PL8-F6 PLAP EP194 PMS2 EPR3947; EP51 Pneumocystis jirovecii 3F6 Podoplanin / D2-40d D2-40 Prealbumin EP2929Y Progesterone Receptor BSB-2; 1A6 Progesterone Receptor RBT22; EP2 Progesterone Receptor PR88 (Insite) Prolactin PRL02; BGX031A Prolactin EP193 Prostein / P501S ZR-9 Ps2 Estrogen PS2.1 Psa ErPr8 PSAP PASE/4LJ; B M-NA PSAP EP53 PSMA EP192; SP29 PSP94 / MSMB EP203 PTEN 6H2.1 PTEN RBT-PTEN; SP218 PU.1 EP18 Renal Cell Carcinoma PN-15; RCC-26 Retinoblastoma (Rb) 1F8 S- 100Beta EP32 S-100 4C4.9; 15E2E2 S-100 S-100A1 EP184 S-100A6 EP313 S-100A8 / MRP8 EP90 S-100A9 EP185 S-100P EP186 SALL4 6E3
6 SALL4 EP299 Sarcomeric Actin ZMSA-5 SATB2 EP281 Secretin SMAD4/DPC4 BSB-63 SMAD4/DPC4 RBT-SMAD4 Smoothelin R4A Somatostatin EP130; Somatostatin BSB-113 SOX-10 BSB-62 SOX-10 EP268 SOX-11 CL0142 SOX-2 EP103; SOX-9 EP317 Spectrin RBC2/3D5 Spectrin EP251 Stat5- Alpha (C-Term) E289 STAT6 EP325; Stathmin EP247 Substance P Survivin EP119; EP2880Y SV40 Pab101 Synaptophysin EP158; Synaptophysin Snp88 T.Gondii TAG-72 BSB-21 (Tag72-22); B72.3 Tag-90, Bca B6.2 Tau BSB-115; Tau5; Tau2 T-Bet/TBX-2 EP263 TCL1 EP105 TCR Beta F1 8A3 TdT TdT88 TdT EP266; RBT-TdT; TFE3 EP285 Tfpu.1 EPR3159Y Tgf-Alpha TGF88 Thyroglobulin 2H11/6E1; BSB-49; 2H11 Thyroglobulin EP250 Thyroid Peroxidase EP159 Thyroxine D5 TIA-1 TIA-1; 2G9A10F5 TLE1 1F5 Topo2 Alpha EP1102Y Topoisomerase II EP93; RBT-Topo2a Alpha TRAcP 9C5 Transferrin HT1/ Treponema pallidum Tryptase G3 Tryptase EP259 TSH BSB-56; 5404 TSH EP254; TTF-1 8G7G3/1; BGX-397A Tyrosinase BSB-6; Ty/G5 Uroplakin III EP321; VZF SG1-1, SG1-SG4, NCP-1 & IE-62 VEGF RBT-VEGF; Villin CWWB1; ID2C3 Villin EP163 Vimentin V9; LN6 Vimentin EP21 Vip WT1 6F-H2 Zap-70 2F3.2; ZAP70-C3 Zap-70 EP52; YE291 For more information or to place an order, contact us.
2016 Antibodies by Application
2016 by Application Higher Affinity Higher Sensitivity Higher Specificity New Rabbit Monoclonal ALK, EP301 Amyloid A, EP335 B7H3/CD276, RBT B7H3 bcl6, EP278 BRAF V600E, RM8 C4d, EP273 CD5, RED1 CD8, EP334
antibodies by application
antibodies by application Higher Affinity Higher Sensitivity Higher Specificity A selection of Over 460 Rabbit and Mouse Monoclonal For Use in Clinical and Research Applications Bio SB s RBT & MMab s BSB
Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK UCL-Advanced Diagnostics 1st Floor, Rockefeller Building 21 University Street London WC1E 6JJ Contact: David Allen Tel: +44 (0)20 7679 6912
Products for Molecular Pathology
Products for Molecular Pathology At Bio SB our passion is providing biomedical laboratories with the tools to improve the diagnosis, prognosis and therapies that benefit patients worldwide. Bio SB is proud
NEW IHC A n t i b o d i e s
NEW IHC Antibodies TABLE OF CONTENTS NEW IHC ANTIBODIES from Cell Marque CITED1 (5H6).... 1 Claudin 7 (5D10F3).... 1 GATA1 (4F5).... 1 Transgelin (2A10C2).... 1 NEW IHC ANTIBODIES using RabMAb Technology
Protocols for Zytomed Systems antibodies on fully automated IHC staining systems date of issue: September 20, 2012
Protocols for Zytomed Systems antibodies on fully automated IHC staining systems date of issue: September 20, 2012 These protocols were provided by customers. Under no circumstances shall Zytomed Systems
IHC Panels as an Aid in Diagnostic Decision Making
IHC Antibody Test Selection Using a Panel Approach Steven Westra B.S. Reagent Product Specialist Leica Biosystems IHC Panels as an Aid in Diagnostic Decision Making Diagnostic Use of Tumors Using Algorithms
Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
Schedule of ccreditation United Kingdom ccreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK External Quality ssessment Services for Cancer Diagnostics CIC Issue No: 005
The role of immunohistochemistry in surgical pathology of the uterine corpus and cervix
The role of immunohistochemistry in surgical pathology of the uterine corpus and cervix Prof. Ben Davidson, MD PhD Department of Pathology, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway
In Situ Hybridization Immunohistochemistry
2013-2014 In Situ Hybridization Immunohistochemistry A History of Delivering Superior Products Genemed Biotechnologies, Inc. was founded in 1987 and is located in the center of the South San Francisco
Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK Christie Hospital Manchester M20 4BX Contact: Neil Wrathall Tel: +44 (0) 161 918 7264 Fax: +44 (0) 161 446 8549 E-Mail: neil.wrathall@christie.nhs.uk
Breast - ductal carcinoma CK7 ER PR GATA3 Mammaglobin (50-70%) GCDFP-15 (50-70%) E-cadherin HMWCK CK20 PAX2 ER/PR/HER2 on all newly diagnosed cases
Adrenal cortical carcinoma Inhibin Synap Melan-A Calretinin Vimentin Chromogr CK7 CK20 Breast - ductal carcinoma CK7 ER PR GATA3 Mammaglobin (50-70%) GCDFP-15 (50-70%) E-cadherin HMWCK CK20 PAX2 ER/PR/HER2
Cleveland Clinic Laboratories
Cleveland Clinic Laboratories Anatomic Pathology Special s Group I for Microorganisms Special s Group I 88312 Fite stain Gomori s methenamine silver (GMS) Gram Gridley PAS/light green counterstain Warthin-Starry
ADVANCED STAINING PRODUCT CATALOG. In Situ Hybridization Probes Immunohistochemistry Antibodies Detection Systems Ancillary Reagents
2017 ADVANCED STAINING PRODUCT CATALOG In Situ Hybridization Probes Immunohistochemistry Antibodies Detection Systems Ancillary Reagents A History of Delivering Superior Products Genemed a wholly-owned
Cleveland Clinic Laboratories
Cleveland Clinic Laboratories Anatomic Pathology Special Stains Group I for Microorganisms Special Stains Group I 88312 Fite stain Gomori s methenamine silver (GMS) Gram PAS/light green counterstain Warthin-Starry
Technology from Abcam
CD2 (EP222) CD2 is one of the earliest T-cell lineage restricted antigens to appear during T-cell differentiation and only rare CD2+ cells can be found in the bone marrow. Anti-CD2 is a pan-t-cell antigen
CURRENT AND EMERGING CANCER DIAGNOSTIC TESTS Emerging Assays, and Companies Developing New Technologies and Products.
CURRENT AND EMERGING CANCER DIAGNOSTIC TESTS Emerging Assays, and Companies Developing New Technologies and Products Table of Contents Major Current And Emerging Cancer Diagnostic Tests 1. Introduction
Solutions for IHC. Immunohistochemistry Products 2018 Catalog
Solutions for IHC Immunohistochemistry Products 2018 Catalog Immunohistochemistry Products In an industry where seemingly small decisions can have huge implications and the quality of your diagnosis is
Covering the continuum with standardof-care, innovative, customized, and clinical research options
Pharma Services Full Service Testing Menu Anatomic Pathology Genomics MultiOmyx Flow Cytometry CDx & IVD Cytogenetics FISH Data Comprehensive testing from one responsive laboratory Covering the continuum
TEST MENU
CISH EBV (EBER1 RNA) EBVISH 88365 CISH Kappa by ISH 88365 or 88364 CISH Lambda by ISH 88365 or 88364 Cytogenetics Chromosomal Analysis Cytogenetics 88237, 88264, 88280, 88291 (may include 88285 or additional
Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK Cellular Pathology Laboratory Contact: Breege Nicholson Queen Elizabeth Hospital Tel: +44 (0) 208 333 3000 ext. 8478 Stadium Road E-Mail:
International Catalogue 2016/2017
Detection Cell Control Arrays Accessory Reagents International Catalogue 2016/2017 Immunohistochemistry Selected Reagents for Diagnostics and Research Content Antibodies Positive control list for primary
DOUBLE STAINS. Toll-Free: Direct:
DOUBLE STAINS CD61 + CD71 DAB Brown: CD61 Alk. Phos. Red: CD71 Bone Marrow DAB Brown: Megakaryocytes Alk. Phos. Red: Erythroid Precursors 400x CD61 (2f2) 0.1 ml concentrate............. 161M-14 0.5 ml
Charles Halsey, DVM, PhD, DACVP Pfizer, Inc. IHC Resources
Charles Halsey, DVM, PhD, DACVP Pfizer, Inc. IHC Resources 1 IHC Identification Targets Specimens Controls 2 Tissue controls Trouble Spots 3 The Key to Description IHC Description 4 Intermediate Filaments
Differential diagnosis of HCC
Hepatocellular Carcinoma Quest for an Ideal Immunohistochemical Panel Sanjay Kakar, MD UCSF Differential diagnosis of HCC Hepatocellular lesions Adenoma, FNH, HG dysplasia Adenocarcinoma CholangioCA, metastasis
The unkown primary tumour: IHC Classification, antibody selection, protocol optimization, controls and EQA (part II)
The unkown primary tumour: IHC Classification, antibody selection, protocol optimization, Mogens Vyberg Professor of Clinical Pathology Director of NordiQC Aalborg University Hospital, Aalborg, Denmark
TEST MENU
1p36/19q13 - Oligodendroglioma Oligodendroglioma Panel test (1p36/1q25 and 19q13/19p13) 88374x2 1q21+1p21 Myeloma Panel test 88374 7q31 / del 7q 7q31/CEP7 88374 11q22.3 (ATM) CLL/SLL panel test 88374 11q23
IIImmunohistochemistry (IHC) Outreach Services
IIImmunohistochemistry (IHC) Outreach Services Note type of fixative used if not neutral buffered formalin. Note type of tissue/specimen Unless specified otherwise, positive and negative controls react
The Panel Approach to Diagnostics. Lauren Hopson International Product Specialist Cell Marque Corporation
The Panel Approach to Diagnostics Lauren Hopson International Product Specialist Cell Marque Corporation Cell Marque Rocklin, California About Cell Marque: IVD primary antibody manufacturer Distributors
TEST MENU
1p36/19q13 - Oligodendroglioma Oligodendroglioma Panel test (1p36/1q25 and 19q13/19p13) 88374x2 1q21+1p21 Myeloma Panel test 88374 7q31 / del 7q 7q31/CEP7 88374 11q22.3 (ATM) CLL/SLL panel test 88374 11q23
C.L. Davis Foundation Descriptive Veterinary Pathology Course
C.L. Davis Foundation 2015 Descriptive Veterinary Pathology Course IHC Resources IHC Identification Targets Antibodies Antibodies 1 Antibodies Specimens Antigen Retrieval Unmasks antigen epitopes Methods
IHC Reagents & Kits. CE/IVD Certified
IHC Reagents & Kits CE/IVD Certified BioSiteHisto Nordic BioSite wants to make diagnostic work easier. For this purpose, we have selected a number of markers, which are frequently needed for diagnostics
Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK operating as North East Essex and Suffolk Pathology Service (NEESPS) Cellular Pathology Contact: Lynn Partridge Ipswich Hospital Tel: +44
Schedule of Accreditation issued by United Kingdom Accreditation Service High Street, Feltham, Middlesex, TW13 4UN, UK
21-47 High Street, Feltham, Middlesex, TW13 4UN, UK Cellular Pathology Pathology Department Northampton General Hospital Cliftonville Northampton Northamptonshire NN1 5BD Contact: Mary Pendleton Tel: +44
2016 New Antibodies and Products for Molecular Pathology
2016 New Antibodies and Products for Molecular Pathology Bio SB is excited to introduce over 50 new IVD biomarkers for use in Immunohistochemistry. All antibodies are available in concentrate and convenient
OncoMir Library Cancer Type Target Gene
OncoMir Library Cancer Type Target Gene hsa-let-7a-1 Breast Cancer, Lung Cancer H RAS, HMGA2, CDK6, NRAS hsa-let-7a-2 Breast Cancer, Lung Cancer H RAS, HMGA2, CDK6, NRAS hsa-let-7a-3 Breast Cancer, Lung
Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK Cellular Pathology Contact: Dr Nicola Chaston East Kent Hospitals University Tel: +44 (0)1233 616183 NHS Foundation Trust Fax: +44 (0) 01233
Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK Issue No: 002 Issue date: 05 March 2018 Berkshire and Surrey Pathology Services Department of Histopathology Wexham Park Hospital Slough Berkshire
Histopathological diagnosis of CUP
Histopathological diagnosis of CUP Dr Karin Oien karin.oien@glasgow.ac.uk Disclosure slide Dr Karin Oien has no financial interests in any company mentioned in this presentation. Dr Karin Oien is conducting
The impact of proficiency testing on lab immunoassays
The impact of proficiency testing on lab immunoassays Mogens Vyberg Professor of Clinical Pathology Director of NordiQC Aalborg University Hospital, Aalborg, Denmark Nordic Immunohistochemical Quality
Your single-source laboratory solution. Antibody Library
Your single-source laboratory solution. Antibody Library A-ACT Alpha-1 antichymotrypsin; histiocytes; pancreatic pseudopapillary tumor A-AT Alpha-1-antitrypsin; inherited AAT deficiency ACTH Adrenocorticotropic
INTERPRETATION OF IMMUNOHISTOCHEMICAL STAINS - DIFFICULTIES AND PITFALLS. Gabor Fischer Diagnostic Services Manitoba University of Manitoba
INTERPRETATION OF IMMUNOHISTOCHEMICAL STAINS - DIFFICULTIES AND PITFALLS Gabor Fischer Diagnostic Services Manitoba University of Manitoba IHC INTERPRETATIONS LOCAL DATA Diagnostic Services Manitoba Number
Tissue-based Immunohistochemical Biomarker Expression in Malignant Glandular Lesions of the Uterine Cervix: a Systematic Review
Tissue-based Immunohistochemical Biomarker Expression in Malignant Glandular Lesions of the Uterine Cervix: a Systematic Review Sandra Lee MD, FRCPC 1 *, Vikrant V. Sahasrabuddhe, MBBS, DrPH 2 *, Diana
Tumor Markers: Granular Analysis of the US Market Supplier Shares and Forecasts for 40 Cancer Diagnostic Tests. List of Tables
Tumor Markers: Granular Analysis of the US Market Supplier Shares and Forecasts for 40 Cancer Diagnostic Tests List of Tables Tumor Marker Classification ACTH Tests AFP Tests Beta-2 Microglobulin Tests
AVAILABLE BIOMARKER ASSAYS
AAILABLE BIOMARKER ASSAYS alidation Alpha-2-microglobulin ELISA Anti-CD71/anti-platelet/propidium iodide Anti-KLH IgG ELISA,, Dog, Minipig, Apoptotic, necrotic and dead cells (bone marrow) B (activated
Immunohistochemistry. Potential and challenges To be or not to be
Immunohistochemistry Potential and challenges To be or not to be Søren Nielsen Scheme Manager NordiQC Aalborg University Hospital, Denmark Vårmöte 19.05.2016 Karlstad Overview IHC project coordinator at
Reporting of carcinoma of unknown primary tumour (CUP)
Reporting of carcinoma of unknown primary tumour (CUP) Prof John Schofield Kent Oncology Centre with grateful thanks to Dr Karin Oien University of Glasgow Royal College of Pathologists Cancer datasets
recommended for detecting myoepithelial cells.
Myosin SMMHC stained on normal breast tissue (MSK081) p63 stained on breast carcinoma (MSK087) The expanding role of immunohistochemistry in from atypical ductal hyperplasia or low-grade breast pathology
Nordic Immunohistochemical Quality Control
Nordic Immunohistochemical Quality Control Immunohistochemistry in the classifiation of neoplasias of the alimentary tract & External Quality Assurance of Immunohistochemistry for GI cancer markers Mogens
Thermo Scientific UltraVision Quanto for Immunohistochemistry The New Generation Micro-Polymer Detection System
Thermo Scientific for Immunohistochemistry The New Generation Micro-Polymer Detection System highest sensitivity sharp crisp clear shorter incubation times UltraVision Quanto the new Micro-Polymer System
Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK Department of Cellular Pathology Forth Valley Royal Hospital Stirling Road Larbert FK5 4WR Contact: Suzanne Ferra Tel: 01324 566643 Tel: +44
Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
Schedule of ccreditation United Kingdom ccreditation Service ccredited to Department of Cellular & Molecular Pathology ntrim LBS ntrim rea Hospital 45 Bush Road ntrim BT41 2RL Contact: Jackie Jamison Tel:
BEST PRACTICES IN THE APPLICATION OF IMMUNOHISTOCHEMISTRY TO DIAGNOSTIC UROLOGIC PATHOLOGY: LESSONS FROM USES & ABUSES
BEST PRACTICES IN THE APPLICATION OF IMMUNOHISTOCHEMISTRY TO DIAGNOSTIC UROLOGIC PATHOLOGY: LESSONS FROM USES & ABUSES Mahul B. Amin Professor & Chairman Department of Pathology & Laboratory Medicine Cedars-Sinai
Review and Updates of Immunohistochemistry in Selected Salivary Gland and Head and Neck Tumors
Review and Updates of Immunohistochemistry in Selected Salivary Gland and Head and Neck Tumors. Monophasic tumors : myoepithelioma, acinic cell carcinoma, and salivary duct carcinoma. Biphasic tumors includes
Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK North Tyneside General Hospital Rake Lane North Shields Tyne & Wear NE29 8NH Contact: Ian Taylor Tel:
Dilution Factor Serum Plasma Urine CSF (Other)
R-PLEX s and Assay/Antibody Combinations The tables below provide the dilution factors and primary diluent combinations for samples tested with R-PLEX s. These dilution factors and diluent combinations
IMMUNOPROFILES OF THE MAJOR RENAL NEOPLASMS (%staining)
Stain Clear Cell Papillary IMMUNOPROFILES OF THE MAJOR RENAL NEOPLASMS (%staining) Chromophobe Collecting Duct Carcinom a Sarcomatoid Xp11 Translocat ion Dr Jon Oxley See also www.jonoxley.com Page 1 MTSCC
Zytomed Systems GmbH
Zytomed Systems GmbH Anhaltiner Straße 16 14163 Berlin hone +49 30 80 49 84 990 Fax +49 30 80 49 84 999 international@zytomed-systems.de www.zytomed-systems.com 2 Content ositive control list for primary
Advanced Staining Catalog
Advanced Staining Catalog Novocastra TM IHC Antibodies, Probes & Leica BOND Reagents 2014 USA Edition Pathologists see the difference Over 20 Years of Expertise: Trust our IHC and ISH solutions to deliver
The clinically challenging entity of liver metastasis from tumors of unknown primary
The clinically challenging entity of liver metastasis from tumors of unknown primary Xuchen Zhang, MD, PhD Associate Professor of Pathology Department of Pathology Yale University School of Medicine Liver
Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK Department of Cellular Pathology Contact: Karen Wignall Royal Preston Hospital Tel: +44 (0) 1772 523108 Sharoe Green Lane E-Mail: karen.wignall@lthtr.nhs.uk
Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK Paediatric Histopathology Western Bank Sheffield S10 2TH United Kingdom Contact: Tel: +44 (0) 1142 717240 Fax: +44 (0) 1142 706121 E-Mail:
Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK Dermatopathology Immunodermatology St. John s Institute of Dermatology South Wing, Staircase C St. Thomas Hospital Westminster Bridge Road
Schedule of Accreditation - draft issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
- draft 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK Royal Bournemouth & Christchurch Hospitals NHS Foundation Cellular Pathology Department Royal Bournemouth Hospital Castle Lane East
CARCINOMA OF UNKNOWN PRIMARY: DIAGNOSTIC APPROACH USING IMMUNOHISTOCHEMISTRY
CARCINOMA OF UNKNOWN PRIMARY: DIAGNOSTIC APPROACH USING IMMUNOHISTOCHEMISTRY Jason L Hornick, MD, PhD Director of Surgical Pathology Director of Immunohistochemistry Brigham and Women s Hospital Associate
Carcinoma of Unknown Primary (CUP)
Metasta c Carcinoma of Unknown Primary: Diagnos c Approach Using Immunohistochemistry James R. Conner, MD, PhD Mount Sinai Hospital Toronto, ON Carcinoma of Unknown Primary (CUP) 3-5% of all new malignant
Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK 05/09/2018 Cellular Pathology Level 2 Esher Wing Galsworthy Road Kingston upon Thames KT2 7QB Contact: Dr Sussan Gharaie Tel: +44 (0)208 934
immunohistochemistry stain offerings
immunohistochemistry stain offerings TRUSTED PATHOLOGISTS. INVALUABLE ANSWERS. www.aruplab.com/ap-ihc OCTOBER MARCH 2017 Information in in this brochure is is current as as of of October March 2017. All
10 years of NordiQC Why are 30% of labs still getting it wrong?
Mogens Vyberg & Søren Nielsen NordiQC Institute of Pathology Aalborg University Hospital Aalborg, Denmark May 29th 2015 10 years of NordiQC Why are 30% of labs still getting it wrong? Nothing to declare
Applications of IHC. Determination of the primary site in metastatic tumors of unknown origin
Applications of IHC Determination of the primary site in metastatic tumors of unknown origin Classification of tumors that appear 'undifferentiated' by standard light microscopy Precise classification
Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK Blizard Institute Core Pathology Pathology and Pharmacy Building Second Floor 80 Newark Street London E1 2ES Contact: Pauline Levey Tel: +44
Cutaneous metastases. Thaddeus Mully. University of California, San Francisco Professor, Departments of Pathology and Dermatology
Cutaneous metastases Thaddeus Mully University of California, San Francisco Professor, Departments of Pathology and Dermatology DISCLOSURE OF RELATIONSHIPS WITH INDUSTRY Thaddeus Mully Course C005 Essential
Cutaneous Mesenchymal Neoplasms with EWSR1 Rearrangement
Cutaneous Mesenchymal Neoplasms with EWSR1 Rearrangement By Konstantinos Linos MD, FCAP, FASDP Bone, Soft Tissue and Dermatopathology Assistant Professor of Pathology Dartmouth-Hitchcock Medical Center
Tumor Markers & Cytopathology
Tumor Markers & Cytopathology Objectives: After learning, student should be able to 1. Describe the basic concepts of tumor markers and Asst. Prof. Prasit Suwannalert, Ph.D. (Email: prasit.suw@mahidol.ac.th)
I. Diagnosis of the cancer type in CUP
Latest Research: USA I. Diagnosis of the cancer type in CUP II. Outcomes of site-specific therapy of the cancer type in CUP a. Prospective clinical trial b. Retrospective clinical trials 1 Latest Research:
Enterprise Interest No disclosures.
Enterprise Interest No disclosures. Secondary Tumours in Uropathology Case 2 PRESENTED AT: EUROPEAN CONGRESS OF PATHOLOGY 18 #ECP2018 Slides are the property of the author. Permission required for reuse.
Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
Schedule of ccreditation United Kingdom ccreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK Issue No: 003 Issue date: 27 pril 2018 ccredited to Leighton Hospital Middlewich
Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK Laboratory locations: Department of Histopathology Royal United Hospitals NHS Foundation Trust Combe Park Bath BA1 3NG Contact: Lesley Shipway
Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK The Princess Alexandra Hospital NHS Trust The Michael Letcher Department of Cellular Pathology The Princess Alexandra Hospital NHS Trust Hamstel
C.L. Davis Foundation Descriptive Veterinary Pathology Course at Louisiana State University
C.L. Davis Foundation 2012 Descriptive Veterinary Pathology Course at Louisiana State University the identification of a tissue constituent in situ by means of a specific antigen-antibody interaction where
THYROID TUMOR DIAGNOSIS: MARKER OF THE MONTH CLUB
THYROID TUMOR DIAGNOSIS: MARKER OF THE MONTH CLUB CHARACTERISTIC OF THE IDEAL TUMOR MARKER Specific Sensitive Easy to perform Easy to interpret Adaptable to FNA Reasonable cost (CHEAP) THYROID TUMOR MARKERS
Tumores de células pequeñas, redondas y azules: diagnóstico diferencial cuando el tiempo apremia
Tumores de células pequeñas, redondas y azules: diagnóstico diferencial cuando el tiempo apremia Sílvia Bagué Servei de Patologia Hospital de Sant Pau Barcelona Soft tissue sarcomas Heterogeneous group
Bead Chemiluminescense IMMULITE 2000, 2000 XPI & 2500
Bead Chemiluminescense IMMULITE 2000, 2000 XPI & 2500 For internal use only / Copyright Siemens AG 2006. All rights reserved. المانھای مھم در روشھای کميلومينسانس: کميلومينسانسر مرحله جداسازی.1.2 Page 2
Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
Schedule of Accreditation 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK Department of Eye Pathology 1 st Floor, Cayton Street Building UCL Institute of Ophthalmology 11-43 Bath Street
Product Catalog.
Product Catalog www.biocare.net Contact Customer Service 7:00 am - 5:00 pm PST Toll Free 800-799-9499 customerservice@biocare.net Contact Biocare Medical Toll Free 800-799-9499 Local 925-603-8000 Fax 925-603-8080
Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK Department of Cellular Pathology Pathology Centre C37 New Cross Hospital Wolverhampton Road Wolverhampton WV10 0QP United Kingdom Contact:
Biomarkers in drug discovery and development. Margit Wissenbach, PhD Dir Business Development Scandinavia
Biomarkers in drug discovery and development Margit Wissenbach, PhD Dir Business Development Scandinavia Aptuit: A Truly Integrated R&D Offering Integrated Discovery Integrated Development IND Candidate
Table of Contents. III. Major Current And Emerging Cancer Diagnostic Tests
Analysis of the Global Cancer Diagnostics Market: Emerging Tests, Technology Assessment, Instrumentation Review, Sales Forecasts by Country and Strategic Profiles of Leading Suppliers Table of Contents
Supplementary Material Correlation matrices on FP and FN profiles
Supplementary Material Correlation matrices on FP and FN profiles The following two tables give the correlation coefficients for the FP profiles and the FN profiles of a single tagging solutions against
Poorly Differentiated Neoplasms of Unknown Primary Site: Diagnostic Usefulness of a Molecular Cancer Classifier Assay
Poorly Differentiated Neoplasms of Unknown Primary Site: Diagnostic Usefulness of a Molecular Cancer Classifier Assay F. Anthony Greco, Wayne J. Lennington, David R. Spigel & John D. Hainsworth Molecular
New Frontiers in Cancer Diagnostics: Global Challenges, Emerging Technologies, Competitive Landscape. Table of Contents
New Frontiers in Cancer Diagnostics: Global Challenges, Emerging Technologies, Competitive Landscape I. Introduction II. Worldwide Market Overview Table of Contents 1. Market Overview 2. Worldwide Market
ACCME/Disclosures. Diagnosing Mesothelioma in Limited Tissue Samples. Papanicolaou Society of Cytopathology Companion Meeting March 12 th, 2016
Diagnosing Mesothelioma in Limited Tissue Samples Papanicolaou Society of Cytopathology Companion Meeting March 12 th, 2016 Sanja Dacic, MD, PhD University of Pittsburgh ACCME/Disclosures GENERAL RULES
Descriptive Immunohistochemistry. Agenda. Agenda. What is Immunohistochemistry? 6/3/2014. Tissue from a dog
Descriptive Immunohistochemistry Tissue from a dog Brian W. Smith, DVM, DACVP JPC, Veterinary Pathology Service Silver Spring, Maryland Descriptive Veterinary Pathology C.L. Davis DVM Foundation Agenda
Additional file 2 List of pathway from PID
Additional file 2 List of pathway from PID Pathway ID Pathway name # components # enriched GO terms a4b1_paxdep_pathway Paxillin-dependent events mediated by a4b1 20 179 a4b1_paxindep_pathway Paxillin-independent
Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK Department of Cellular Pathology Dorset County Hospital Williams Avenue Dorchester DT1 2JY Contact: Sharon Wood Tel: +44 (0)1305 254326 E-Mail:
New Frontiers in the Italian Cancer Diagnostics Market: Business Challenges, Emerging Technologies, Competitive Landscape.
New Frontiers in the Italian Cancer Diagnostics Market: Business Challenges, Emerging Technologies, Competitive Landscape Table of Contents I. Introduction II. Major Product Development Opportunities A.
Utility of liquid biopsies EQA Program Naples, IT Sidney A. Scudder, MD Director, Clinical Science 13 May, 2017
Utility of liquid biopsies EQA Program Naples, IT Sidney A. Scudder, MD Director, Clinical Science 13 May, 2017 picture placeholder Agenda cobas EGFR Mutation Test v2 Ring Trial SQI Semi Quantitative Index
New Frontiers in the European Cancer Diagnostics Market: Business Challenges, Emerging Technologies, Competitive Landscape.
New Frontiers in the European Cancer Diagnostics Market: Business Challenges, Emerging Technologies, Competitive Landscape I. Introduction Table of Contents II. Major Product Development Opportunities
Catalog Supplement. Vol. 10.1
Catalog Supplement Vol. 10.1 Introducing New Products from Cell Marque From Passion to Product to Patient. Cell Marque, a Sigma-Aldrich company, is proud to introduce our next wave of innovative products.
Targeted Agent and Profiling Utilization Registry (TAPUR ) Study. February 2018
Targeted Agent and Profiling Utilization Registry (TAPUR ) Study February 2018 Precision Medicine Therapies designed to target the molecular alteration that aids cancer development 30 TARGET gene alterations